| BRIEF COMMUNICATION |
|
| Year : 2017 | Volume
: 35
| Issue : 4 | Page : 585-587 |
Dosing strategy based on prevailing aminoglycoside minimum inhibitory concentration in India: Evidence and issues
Balaji Veeraraghavan1, Agila Kumari Pragasam1, Abi Manesh2, Priscilla Rupali2, Ramya Iyadurai3, Camilla Rodrigues4, Sangeeta Joshi5, Indranil Roy6, Bhaskar Narayan Chaudhuri7, DS Chitnis8, Dhole Tapan9
1 Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India
2 Department of Internal Medicine and Infectious Disease, Christian Medical College, Vellore, Tamil Nadu, India
3 Department of Medicine, Christian Medical College, Vellore, Tamil Nadu, India
4 Department of Microbiology, PD Hinduja Hospital and Medical Research Centre, Bengaluru, Karnataka, India
5 Department of Microbiology, Manipal Hospital, Bengaluru, Karnataka, India
6 Department of Microbiology, The Calcutta Medical Research Institute, Kolkata, West Bengal, India
7 Department of Microbiology, Fortis Hospital, Anandapur, Kolkata, West Bengal, India
8 Department of Microbiology and Immunology, Choithram Hospital, Indore, Madhya Pradesh, India
9 Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Correspondence Address:
Dr. Balaji Veeraraghavan
Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijmm.IJMM_17_386
Aminoglycosides are important agents used for treating drug-resistant infections. The current dosing regimen of aminoglycosides does not achieve sufficient serum level concentration for the infected bacterial pathogen interpreted as susceptible based on laboratory testing. Minimum inhibitory concentration was determined for nearly 2000 isolates of Enterobacteriaceae and Pseudomonas aeruginosa by broth microdilution method. Results were interpreted based on CLSI and EUCAST interpretative criteria and the inconsistencies in the susceptibility profile were noted. This study provides insights into the inconsistencies existing in the laboratory interpretation and the corresponding clinical success rates. This urges the need for revising clinical breakpoints for amikacin, to resolve under dosing leading to clinical failure.
[FULL TEXT] [PDF]*
|
